You are currently viewing the abstract.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Abstract
This is an interview with Michael Frohman, senior author of a Research Article that appears in this issue of Science Signaling. Frohman’s group has investigated the role of the enzyme phospholipase D1 (PLD1) in the tumor microenvironment. PLD1 produces the lipid phosphatidic acid, which acts as a second messenger in many signaling pathways and promotes proliferation, survival, and metastasis of cancer cells. When tumor cells were implanted into mice lacking PLD1, the resulting tumors were smaller and less vascularized than those that developed in wild-type mice and produced fewer lung metastases. Treating wild-type mice with a PLD1 inhibitor also inhibited tumor growth and metastasis, suggesting that inhibiting the activity of PLD1 might be a useful approach for treating human cancers.
